Moreover, Pan et al. described that vorinostat reverses epithelial-mesenchymal transition through direct targeting of Ubiquitin Conjugating Enzyme E2 C (UBE2C), thereby controlling cervical cancer cell proliferation through the ubiquitination pathway [59]. This evidence concerns the gene UBE2C and cervical carcinoma.